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Abstract: Ingenol derivatives with varying degrees of oxidation were prepared by two-phase terpene synthesis.T his strategy has allowed access to analogues that cannot be prepared by semisynthesis from natural ingenol. Complex ingenanes resulting from divergent C À Ho xidation of ac ommon intermediate were found to interact with protein kinase Ci nam anner that correlates well with the oxidation state of the ingenane core.E ven though previous work on ingenanes has suggested astrong correlation between potential to activate PKCd and induction of neutrophil oxidative burst, the current study shows that the potential to activate PKCbII is of key importance while interaction with PKCd is dispensable. Thus,k ey modifications of the ingenane core allowed PKC isoform selectivity wherein PKCd-driven activation of keratinocytes is strongly reduced or even absent while PKCbIIdriven activation of neutrophils is retained.
Protein kinase C( PKC) is af amily of protein kinase enzymes that play ac entral role in controlling cell metabolism, growth, and apoptosis by phosphorylating serine and threonine residues of al arge number of proteins involved in intracellular signal transduction. [1] PKCs are categorized into three subfamilies:1 )classical/conventional PKCs (cPKCs) consisting of PKCa,P KCbI, PKCbII, and PKCg isoforms, 2) novel PKCs (nPKCs) consisting of PKCd,P KCe,P KCq, and PKCh isoforms,and 3) atypical PKCs (aPKCs) consisting of PKCz and PKCi isoforms,w hich share less sequence homology with the two other classes.F or activation, the cPKCs require both the endogenous second messenger diacylglycerol (DAG)a nd Ca 2+ ,w hereas the nPKCs only require DAGt ob ea ctivated. In contrast, neither DAGn or Ca 2+ are required for the activation of aPKCs. [2] DAG activates cPKCs and nPKCs by binding to the regulatory C1 domain. Interestingly,the C1 domain is also present in other proteins like RasGRPs,w here it plays ac ritical role in the interaction with ingenol mebutate (2,F igure 1A). [3] Figure 1. A) Previously synthesized ingenane targets:ingenol (1), ingenol mebutate (2;the active ingredienti nPicato), and an ester derivative 3.B )Current ingenane targets with varying oxidation states. C) Asynthetic plan that maximizes divergency from previously synthesized intermediate 15.
Ingenol mebutate (2)a nd several other structurally diverse natural products,including phorbol esters,bryostatins, prostratin, gnidimacrin, mezerein, and resiniferatoxin, act as potent DAGmimetics by binding to the C1 domain of cPKCs and nPKCs. [4] However,while avariety of natural compounds activate PKCs,t he outcome of PKC activation by as pecific compound is highly context-dependent, with the individual cellular targets (and off-targets) and overall effects determined by the specific isozyme(s) involved, the timing of PKC activation, the cell type,and the signaling environment. [5] This is reflected by comparing the biological activities of 12-Otetradecanoylphorbol-13-acetate (TPA), bryostatin 1, and ingenol mebutate (2): the first is as trong tumor promoter, the second shows antiproliferative properties,a nd latter has antitumoral properties and represents the active ingredient in Picato,amarketed product for the topical treatment of actinic keratosis (solar keratosis). [6] Thet wo-phase total synthesis of ingenol (1) [7] and the semisyntheses of ingenol mebutate (2) [8] and ingenol 3-amethylcyclohexanecarboxylate (3) [9] were reported previously ( Figure 1A ). Tw o-phase terpene synthesis can both enable scalable access to the parent natural product and constitute atemplate for preparation of analogues with deepseated changes. [10] In the case of 1,the latter cannot be rapidly obtained through semisynthesis or synthetic biology.I nt his work, an exploratory oxidase phase ( Figure 1B )featuring 13 CÀHoxidations is used to systematically evaluate the role of the four hydroxy groups in the biological activity of ingenol (1) .
Thedecision to focus primarily on the oxidation pattern of the ingenanes was guided by the hypothesis that the alcohol functionalities have the greatest potential to fine-tune interactions with PKCs.T he work by Winkler and co-workers demonstrated that simultaneous removal of the C18 and C19 methyl groups and the dimethylcyclopropane moiety resulted in as ignificant loss of affinity to PKCa, [11] although the contribution to the loss of affinity from each group was not clarified. Analogues 4-14 therefore retain these motifs,w ith only af ew C18 desmethyl derivatives synthesized over the course of this research program as an initial step to dissect the importance of these lipophilic groups (see below). Ingenol 3-a-methylcyclohexanecarboxylate (3)was chosen as the reference ester because 3 has previously been shown to be more chemically stable and more potent than ingenol mebutate (2). [9] Thes ynthesis of analogues 3-14 was accomplished by atwo-phase strategy that closely resembles our previous work on the total synthesis of ingenol (1) . [7] Since intermediate 15 (prepared from 3-carene in 6s teps including an efficient Pauson-Khand reaction) is now being synthesized in greater than 100 gram batches at Kemxtree,i tw as the most logical point of divergence to access 3-14 in am inimal number of synthetic operations ( Figure 1C ). Thesynthetic oxidase phase outlined below delivered novel hydroxylation patterns on the ingenane skeleton and necessitated chemo-and regioselective solutions to the complex problem of divergently functionalizing the ingenane core.S elective CÀHo xidation was ultimately the enabling method to address this challenge,a nd at otal of 13 CÀHo xidation events were carried out in the synthesis of analogues 3-14 and 3' '.T ot he best of our knowledge,t his represents the most extensive use to date of C À Ho xidation in the biological evaluation of an atural product family. [12] To access many different oxidation levels of the ingenane skeleton, Pauson-Khand product 15 was first elaborated into the "more-oxidized cyclase-phase endpoint" 16 and "lessoxidized cyclase-phase endpoint" 17 in 4s teps and 3s teps, respectively (Figure 2 ; see the Supporting Information for details). Although cyclase-phase endpoint 16 had been previously elaborated into ingenol (1; Path A), [7] in this work, ac ritical modification was made wherein as toichiometric osmium-mediated dihydroxylation step was rendered catalytic (see the Supporting Information for details). Thereafter, in ad iverging pathway, 16 was transformed into C4-deoxy analogues 6 and 8 (Path B). The" allylic oxidation panel" previously developed during our synthesis of taxuyunnanine D [13] was employed throughout this work. After extensive experimentation, ak ey Pd(OH) 2 /TBHP step [14] (20!21)w as found to be critical to the success of this reaction sequence,s ince the allylic oxidation at C3 was only possible using these conditions.The product of this oxidation reaction, 21,w as structurally confirmed by X-ray analysis to establish the relative stereochemistry of the generated analogues 6 and 8 (see the Supporting Information for details). Likewise," less-oxidized cyclase-phase endpoint" 17 was treated with Pd(OH) 2 and TBHP to give allylic alcohol 22,w hich was further oxidized to give analogues 5 and 7 (Path C).
An interesting point of divergence occurred when using intermediate 17,s ince treatment of 17 with Pd(OH) 2 and TBHP gave C3-oxidized ingenane 22,b ut SeO 2 oxidation gave C19-oxidized product 24 (Path D). Thel ack of C3 oxidation when using SeO 2 allowed access to analogues 10 and 12,which are devoid of the C3,C4,C5-hydroxy triad that is so prominent in ingenol (1). Finally,t ransformation of cyclase-phase endpoint 17 into ingenol analogue 14 led to another curious finding in oxidation chemistry (Path E): although 14 did not react under Pd(OH) 2 /TBHP conditions,it was successfully oxidized at C3 when using our recently developed Cr V -based allylic oxidation, [13] giving ingenane 26 with an inverted stereocenter at C3. This inversion of stereochemistry did not obstruct the synthetic plan, since it 26 was easily converted into analogues 11 and 9 in 1a nd 2 steps,respectively.Assuch, 10 new ingenol analogues (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) were synthesized, with most of these products containing an a-methylcyclohexanecarboxylate ester for stability and potency. Thef eat of generating many derivatives with vastly different oxidation states was achieved by embracing the subtleties of CÀHoxidation in complex-molecule synthesis. [15] Aside from these analogues with varying oxidation levels, some desmethyl analogues of ingenol (1)were also prepared ( Figure 3 ). Much like in the previous route to 1, [7] an 11-desmethyl analogue of 15 (herein denoted as 15' ')w as prepared in 6s teps from 3-carene (see the Supporting Information). Following the remaining steps in the previous synthesis of 1,analogues 4' ' and 1' ' were generated, along with a-methylcyclohexanecarboxylate ester 3' '.T hese desmethyl Angewandte Chemie analogues surprisingly did not show reduced potency( see below).
Ap reviously described [9] screening cascade was used to characterize immune response-related effects of C20-hydroxylated ingenol analogues 5, 6, 9, 10, 13 and desmethyl compound 3' '.T hus,s tudies were conducted for in vitro activation of human recombinant PKCd,s timulation of IL-8 release in primary epidermal keratinocytes, and induction of oxidative burst (release of reactive oxygen species) in polymorphonuclear leukocytes (PMN;n eutrophils). PKCd has been shown to be critical for TPA-induced keratinocyte differentiation. [16] In this cell type,P KCd also exerts proapoptotic functions and is critical for the regulation of both intrinsic and extrinsic apoptosis pathways. [17] Thefinding that PKCd expression is low or even absent in some human squamous cell carcinomas suggests that it functions as atumor suppressor in keratinocytes. [18] In addition to its role in keratinocytes,P KCd is also required for the attraction of . .
Angewandte
Communications neutrophils,w hich are immune cells that are an essential component of the antitumoral action of ingenol mebutate (2) . [19] This is supported by findings in cultured human endothelial cells,w here 2 induces secretion of the neutrophil-attracting chemokine IL-8 and surface expression of the adhesion molecules E-selectin and ICAM-1 in aPKC-dependent manner. Knockdown of PKCd by small interfering RNA (siRNA) completely abolished neutrophil recruitment to endothelial cells subsequently treated with 2,t hus proving the essential role of this specific isoform in the process. [20] Comparison of the activity of ingenol analogues 5, 6, 9, 10, 13 with the reference ingenol ester 3 in the PKCd activation and the keratinocyte IL-8 release assay revealed ac lear structure-activity relationship (Figure 4) . Removal of asingle hydroxy group at either position C5 or C4 (compounds 5 and 6,r espectively) only resulted in am oderate loss of potency, and removal of both the C4-and C5-hydroxy groups (9) resulted in am arked loss in activity:a pproximately 100-fold in PKCd activation and 16-fold in IL-8 induction when compared to 3.Anear-complete loss of activity was observed for analogue 10,inwhich the ester function was moved to the C19 position, and C3,C4,C5-des-hydroxy ingenol 13 was totally inactive.S urprisingly,d espite previous literature data, [11] removal of the C18-methyl group (compound 3' ')d id not negatively affect the potencyof3.
Remarkably,t he data for neutrophil oxidative burst induction indicates that the C4,C5-des-hydroxyl analogue 9 is almost as potent as the reference ingenol ester 3 despite its low potencyi na ctivating PKCd and inducing IL-8 in keratinocytes.Furthermore,the C19-ester 10 was established as an agonist of PKCd with as ub-micromolar half-maximal effective concentration (EC 50 ). This finding was unexpected because 10 was completely inactive in both the PKCd and keratinocyte IL-8 assay and also because earlier work on C3-ingenol esters had shown astrong correlation between PKCd activation and oxidative burst induction. [21] Thus,i tw as hypothesized that ad ifferent PKC isoform was critical for oxidative burst induction in neutrophils.I no rder to identify relevant candidates,mRNAexpression levels of classical and novel PKC isoforms were determined in primary human keratinocytes and neutrophils (see the Supporting Information). These data showed that PKCb,w hich was barely detectable in keratinocytes,w as clearly the dominating isoform in neutrophils,with expression levels more than tenfold higher than that of PKCd and any of the other isoforms.A critical role of classical PKC isoforms and specifically PKCb in neutrophils had been suggested earlier [22] and is supported by studies showing approximately 50 %inhibition of phorbolester-induced oxidative burst in neutrophils isolated from PKCb-knockout mice and in primary human neutrophils treated with as mall-molecule PKCb inhibitor. [23] Since PKCbIa nd PKCbII are generated by splicing from as ingle gene and dont differ in their regulatory (DAG,C a 2+ )a nd catalytic domains, [24] we decided to determine the effect of compounds 5, 6, 9, 10, 13,and 3 on the activation of PKCbII because this isoform has been reported to be expressed at higher protein levels in human neutrophils [25] (Figure 4 ). In line with our hypothesis, 9 and 10 activated PKCbII with EC 50 Angewandte Chemie values of 6a nd 828 nm,r espectively.T hese values are in the same range as those observed for the induction of oxidative burst in neutrophils,thus indicating that activation of PKCbII rather than PKCd is critical for this process.Ofnote,the EC 50 values for 5, 6 and 3 were all in the sub-nanomolar range.
In summation, the first systematic study of single-and multiple-functional-group alteration on ingenol (1)h as been accomplished using two-phase terpene synthesis.Enabled by over ad ozen C À Ha ctivation steps,m odifications of the ingenol core scaffold resulted in analogues with exquisite PKC isoform specificity,i.e., molecules that show low or even absent activity on PKCd and keratinocytes but retain the potential to activate PKCbII and neutrophils.B eyond their utility as pharmacological tools,such compounds could be of use in therapeutic applications where one would like to avoid the activation of keratinocyteso rendothelial cells but retain activity in neutrophils.This work highlights the power of twophase terpene synthesis and CÀHo xidation to enable the preparation of rationally designed pharmacological probes to illuminate complex biological processes.
